Drawing back to why this company is valuable on my first post i mentioned goodwill. You buy the company through aquisition any peice paid above mkt value gets you an asset in return. You never see the years of losses incurred during development. The life cycle of the deal now is 10 times faster. Micros went from 5 milliom to 1.5 billion in 30 years to be aquired by oracle for 5 billion. Equate the same variales divide by ten that is how long till aqisition here.
If we took a look back in time to MCRS. A novel idea that filled a need and grew not by the product.Micros workstation but the intellectual property. The movel concept is not a multi asaay test it is the accuracy efficiency and ease of access from purchase derived from tens of thousands of r and d hours. There is a lot of expense and cap ex and faiked attempts that go into the process. With 5 dollars in cash and 100% increases in 2 quarters uts a tinder bundle that is bellowing smoke and yiu better believe the best in brightest of IT are drawn to such a comapny. It makea for a greeat recruitment tool .i imagine the talent they are grabbing is tremendous. I think this is a 30 dollar compnay in 5-10 years.
If trend continues 2 years and we will see eps. By then aquisition will happen. No aquiring company wants to invent the wheel they want to watch and wait for you to take the training wheels off and just when you are making progress they will stick there foot out annd trip you. Everyone wants to know how and when they will die. Everyone wnats to know what portential faulty genes they may be passing down to there children. No other genetic test provider has a solid and easy to use expiernce that is integrated with an intellectual property ie thier proprietary software developed internally. You have to understand accounting and software development to relate to my valuation. If you buy an intellectual property that has an amtorized value of 100 million for 200 million you do not reliaze a loss you simply increase goodwill. Mygn is not an it company. NVTA is . one gentlman stated they woukd need a novel test wrong they have an IP that drives more efficient cost effective testing. It is similar to the anti japanese car movement of 70s and early 80s . how change is inevitable when efficiently positioned
Sentiment: Strong Buy
Should all work together and present a unified front to the complete annihilation of isis. Soft targets going for pacifist govt like france.prob retaliation for us killing gihadi john that pojoh
If nvta ran an add showcasing to the consumers how they can go online and ordrr thousands of combinations of genetic tests at a reasonable cost . how much traction would that create? More than you could imagine. Dont kid yourself bb owns 40% of ghdx. Nvta is not a dud its an aqusition exp.
I think you are wrong again. As market gets narrow with isolating diseases in subsets of gentic conditions these all in one test are quite resoueceful.
You areconfused. They sold an operational center that was pdrimarily used to develop and produce gmab. It is not in the best interest of shareholders for xoma to be paying for a facility for 300 workers if thry have just laid aof a large % of workforce and are now pivoting towards another area of biotech far more lucrative than the latter. Will it work time will tell. Obviousky the market had concerns oe the stock would not have sropped from 4 something to under a dollar. When they regained complaince and trimmed fat the market took notice and peice jumped. I think those that unloaded above 1.75 were smart to take some off the table as the market may have jimped to conclusions . there is srill one or two more uptick eventa to come .
Lol you guys are nuts . they wouldnt cover the sign and buy shares knowinf what you are inferring that would be collusion. My guess is they may be subletting, moving or its equipment gifted by novartis. Font look into things that hard. Onky way one woukd aquire xoma is if gmab had mkt value . all the rest is not worth the billion dollars you would need to account for # of shares vs equity to exceed the current mkt price. Nut . i got my monsey back plus a few thiudand dollars im happy still holding 10k at avg cost 92 cebts cant cash more uncle sam would kill it
Lol they have $5 per share in cash and provide comprehensive , more cost effective tests than anyone on the market, they have aa solid cloud based irdering platform that by itself is worth a hellof a lot of goodwill. The only thing they lack is a massivesalesforce . either genomic or myriad will buy them plus 20. Well worth it . guess who owns nearly 50% of genomic, baker brother. Connect dots . i woukdnt be suprised if they hve increases holdings again. I bought at 7.20 sold at 9.80 vought again yeaterday. 100% sure to see $10 ,90% sure to see $12 in 2016. I should buy a ton buyt im going to be conservative till it makes a move again.
Does everyone agree that dilution at anythinf under 2.00 is suicide? I am trying to find exanples of something similar and i think cycc is the closest i can find. Reverse split is even worse. Are they dumb enougj to dilute after regaining complaince?
Name one biotech coverrd by oppenheimer , citi, jp morgan and ebc at avg pt of 90 that ever went below 20 dollars name inw lol. I backed up the tryck on xoma at 87 cents just the same
Nike will not aquire lulu. Luku has so many 1-2 register stores in yoga shops . nike is just now getting into retail sector. If nike did aquire lulu it would mean nike wants lulu prime locations to expand their boutique stores. It would be less for competitive eeasons and more for hedging ebtering the us retail market. Maybe vfc corp, ascena retail. Philips van huesan? Those seem more plausible . the latter pvh is who i woukd bet on. .
Jp morgan pt 84. Oppenheimer 135. Citi 90 . rbc 56. ...can anyone find instance where 3/4 collecttively had such bullish rating that failed to achieve fhe lowest covering price target?.... The nice thing is when bio marin gets nod this jumps 30%. Also mitigates risk .
First let me say that this is obviously a beat down before great news . Whether it be an aquisition or earnings beat . With a greate cash per share, a proven revenue maker in the CBR aquistion you have to assume the beat down will end before 30. Thats my bet.
Now the data in the eu trial was far better than us trial. However approval is likely in us for this reasonPatients on Translarna also showed a slower rate of decline in ambulation in eu trial. No data points were discussed in us trial . my guess I s drug works in % and decreasss advance of disease. A few months of quality with their child why wouldnfda say no think about it. Roth iz #$%$. Listen to opp jp not roth.